TARS
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
TARS’s FA Score shows that 0 FA rating(s) are green while.
- TARS’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
TARS’s TA Score shows that 4 TA indicator(s) are bullish.
- TARS’s TA Score: 4 bullish, 6 bearish.
Price Growth
TARS (@Biotechnology) experienced а -2.65% price change this weekfor the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +3.51%. For the same industry, the average monthly price growth was +3.11%, and the average quarterly price growth was -5.53%.
Reported Earning Dates
TARS is expected to report earnings on Nov 06, 2024.
Industries' Descriptions
@Biotechnology (+3.51% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| TARS | |
| Capitalization | 1.25B |
| EBITDA | -144.23M |
| Gain YTD | 59.358 |
| P/E Ratio | N/A |
| Revenue | 83.4M |
| Total Cash | 324M |
| Total Debt | 72.2M |
| TARS | |
|---|---|
| RSI ODDS (%) | 2 days ago 78% |
| Stochastic ODDS (%) | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 87% |
| MACD ODDS (%) | 2 days ago 69% |
| TrendWeek ODDS (%) | 2 days ago 85% |
| TrendMonth ODDS (%) | 2 days ago 81% |
| Advances ODDS (%) | 16 days ago 82% |
| Declines ODDS (%) | 10 days ago 84% |
| BollingerBands ODDS (%) | 2 days ago 74% |
| Aroon ODDS (%) | 2 days ago 82% |
TARS and Stocks
Correlation & Price change
A.I.dvisor indicates that over the last year, TARS has been loosely correlated with PLRX. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if TARS jumps, then PLRX could also see price increases.
| Ticker / NAME | Correlation To TARS | 1D Price Change % | ||
|---|---|---|---|---|
| TARS | 100% | -1.47% | ||
| PLRX - TARS | 38% Loosely correlated | +1.92% | ||
| DNLI - TARS | 35% Loosely correlated | -2.79% | ||
| SVRA - TARS | 34% Loosely correlated | -2.31% | ||
| MDGL - TARS | 33% Loosely correlated | -1.23% | ||
| SPRY - TARS | 33% Loosely correlated | -3.11% | ||
More | ||||